Propofol (2,6-diisopropylphenol) is the most widely used intravenous anesthetic agent in the world, employed for induction, maintenance as a component of TIVA, and procedural sedation across virtually every clinical setting from the operating room to the endoscopy suite to the intensive care unit. Its pharmacological profile combines rapid onset, predictable offset, antiemetic properties, and a smooth quality of induction and emergence that no other IV anesthetic has fully replicated.¹

Mechanism of Action. Propofol produces anesthesia primarily through positive allosteric modulation of the gamma-aminobutyric acid type A (GABA-A) receptor. It binds to specific transmembrane sites on the beta subunit of the GABA-A receptor, enhancing chloride conductance and prolonging channel opening time in response to GABA. At clinical concentrations it also directly activates the GABA-A receptor in the absence of GABA, contributing to its potency. Additional mechanisms include inhibition of N-methyl-D-aspartate (NMDA) receptor activity and activation of two-pore domain potassium channels, which together hyperpolarize neurons in the thalamus and cortex and suppress the ascending arousal network.²

Pharmacokinetics. Propofol follows a three-compartment pharmacokinetic model. After a bolus induction dose, it distributes rapidly to the highly perfused central compartment, reaching peak brain concentrations within 30 to 60 seconds. The initial rapid offset of effect after a single bolus (clinical duration 5 to 10 minutes) is driven by redistribution from the brain and central compartment to muscle; elimination from the body occurs more slowly through hepatic glucuronidation and sulfation, with metabolites excreted renally. The volume of distribution is large (approximately 4 L/kg), reflecting extensive lipid partitioning.¹

Context-Sensitive Half-Time. For infusion-based anesthesia, the relevant pharmacokinetic parameter is the context-sensitive half-time (CSHT): the time required for plasma concentration to fall by 50% after cessation of a continuous infusion of specified duration. Propofol's CSHT rises modestly with infusion duration, from approximately 10 minutes after a 1-hour infusion to approximately 40 minutes after an 8-hour infusion, reflecting gradual saturation of peripheral compartments. This compares favorably to many opioids and to midazolam, which has a markedly prolonged CSHT with extended infusions. The clinical implication is that propofol TIVA remains clinically manageable even after long procedures, with emergence times that are reasonably predictable.³

Cardiovascular Effects. Propofol produces dose-dependent reductions in systemic vascular resistance, mean arterial pressure, and cardiac output. The MAP reduction after an induction bolus is typically 25 to 40% and results from both peripheral vasodilation and a modest reduction in myocardial contractility. Heart rate does not reflexively increase as expected because propofol also blunts baroreceptor responsiveness and may have a mild negative chronotropic effect at higher doses. These hemodynamic effects are exaggerated in patients who are elderly, hypovolemic, or have pre-existing left ventricular dysfunction, in whom induction doses should be reduced by 30 to 50% and administered slowly. Pain on injection is common and is reduced by pretreatment with lidocaine 40 mg IV (administered before propofol into a large antecubital vein) or by admixture of lidocaine with the propofol.¹

CNS Effects. Propofol reduces cerebral metabolic rate for oxygen (CMRO₂) and cerebral blood flow (CBF) in a dose-dependent fashion, producing EEG slowing and ultimately burst suppression at high doses. Unlike volatile agents, it does not cause cerebral vasodilation; the reduction in CBF parallels the reduction in CMRO₂, preserving cerebrovascular coupling. This makes propofol favorable for neuroanesthetic applications. At clinical infusion rates, it preserves cerebral autoregulation better than volatile agents at equivalent depths of anesthesia. Propofol also produces dose-dependent antiemetic effects, likely through 5-HT₃ antagonism and inhibition of dopaminergic signaling in the chemoreceptor trigger zone; subhypnotic infusion rates (10 to 20 mcg/kg/min) have been used for postoperative antiemetic rescue.²

Respiratory Effects. Propofol is a potent respiratory depressant. Induction doses cause apnea in a majority of patients, necessitating airway support or controlled ventilation. At sedation infusion rates, it reduces tidal volume and blunts the ventilatory response to hypercapnia and hypoxia. Unlike the volatile agents, propofol does not cause bronchodilation and is generally regarded as having a neutral effect on airway resistance, though some evidence suggests mild bronchodilatory properties in patients with reactive airways. It does not trigger malignant hyperthermia and is the preferred agent in MH-susceptible patients.¹

Propofol Infusion Syndrome (PRIS). Propofol infusion syndrome is a rare but potentially fatal complication of high-dose prolonged propofol infusion. It is characterized by metabolic acidosis (often with a high anion gap), rhabdomyolysis, cardiac arrhythmias (including Brugada-pattern ECG changes and ventricular fibrillation), acute kidney injury, and hepatomegaly. The mechanism involves impairment of mitochondrial respiratory chain function and beta-oxidation of fatty acids, leading to cellular energy failure. PRIS is predominantly reported in severely ill patients (both adult and pediatric) receiving infusion rates above 4 to 5 mg/kg/hr for more than 48 hours, though cases at lower doses have been reported.³ Propofol is contraindicated for long-term sedation of pediatric patients in the ICU. For adult ICU sedation at high doses or extended duration, triglyceride monitoring and vigilance for early signs of PRIS (unexplained metabolic acidosis, rising creatine kinase) are warranted.

Formulation Considerations. Propofol is formulated in a lipid emulsion (10% soybean oil, 1.2% egg phosphatide, 2.25% glycerol) that supports bacterial growth if contaminated. Strict aseptic technique is required during preparation and administration, and opened vials should be used within 6 to 12 hours per manufacturer guidance. The lipid vehicle contributes approximately 1.1 kcal/mL, which must be accounted for in the nutritional calculations of patients receiving prolonged propofol infusions in the ICU. Propofol turns urine green with chronic high-dose use, a benign phenomenon reflecting the excretion of its quinol metabolites.¹

Ketamine is a phencyclidine (PCP) derivative that produces a pharmacologically distinct anesthetic state unlike any other agent in clinical use. Its primary mechanism is non-competitive antagonism of the N-methyl-D-aspartate (NMDA) receptor, blocking the ion channel pore in a use-dependent and voltage-dependent fashion. This prevents calcium influx through the NMDA receptor channel, disrupting glutamate-mediated excitatory neurotransmission in thalamocortical circuits and limbic structures. The resulting state has been termed dissociative anesthesia: the patient appears awake (eyes may be open, with preserved corneal and cough reflexes) but is disconnected from the environment and unresponsive to pain, with profound analgesia and anterograde amnesia.⁵

Additional Mechanisms. Beyond NMDA antagonism, ketamine has several secondary pharmacological actions that contribute to its clinical profile. It is an opioid receptor agonist (primarily at mu and kappa receptors), which contributes to its analgesic properties at subanesthetic doses. It activates descending monoaminergic inhibitory pathways, augmenting norepinephrine and serotonin-mediated pain suppression. It blocks sodium channels, producing local anesthetic-like effects. And it has anti-inflammatory properties through inhibition of nuclear factor kappa B (NF-kB) signaling that may be relevant in its applications in chronic pain and perioperative analgesia protocols.⁵

Pharmacokinetics. Ketamine is highly lipid-soluble (octanol:water coefficient approximately 5.1) and crosses the blood-brain barrier rapidly, producing anesthesia within 30 to 60 seconds after IV administration and 3 to 5 minutes after IM injection. The clinical duration of a single IV induction dose (1 to 2 mg/kg) is 10 to 15 minutes. Ketamine is hepatically metabolized, primarily by CYP3A4 (cytochrome P450 3A4) and CYP2B6 (cytochrome P450 2B6), to norketamine, an active metabolite with approximately 20 to 30% of the pharmacological potency of the parent compound. Norketamine is then further hydroxylated to inactive metabolites excreted renally. The elimination half-life of ketamine is 2 to 3 hours. Repeated dosing or prolonged infusion leads to accumulation of norketamine, which may prolong clinical effect and contribute to emergence reactions.¹

Cardiovascular Effects. Ketamine is the only induction agent that reliably increases rather than decreases blood pressure and heart rate. It stimulates the sympathetic nervous system centrally (through inhibition of catecholamine reuptake at sympathetic nerve terminals and central sympathetic activation) and releases endogenous catecholamines, producing increases in heart rate, systemic vascular resistance, cardiac output, and myocardial oxygen consumption. Mean arterial pressure typically rises by 20 to 30% after an induction dose. This sympathomimetic cardiovascular profile makes ketamine the agent of choice for induction in hemodynamically unstable patients, including trauma patients in hemorrhagic shock, patients in septic shock, and patients with severe bronchospasm requiring emergency intubation, where propofol or thiopental would cause dangerous hypotension.⁵

An important exception to ketamine's cardiovascular stimulation applies to patients who have depleted their catecholamine stores through prolonged severe illness or severe stress. In this population, the usual sympathomimetic effect may be absent or reversed, and the direct negative inotropic properties of ketamine (which are masked by sympathetic stimulation in intact patients) may become apparent, causing unexpected cardiovascular depression. This is an uncommon but clinically important scenario, most often encountered in patients with profound septic shock who have already received high-dose vasopressor support for extended periods.⁵

Airway Effects. Ketamine preserves pharyngeal and laryngeal tone more than other induction agents, largely because it does not abolish consciousness in the same global sense as propofol or thiopental. Upper airway reflexes are attenuated but not abolished. This property led to the historical characterization of ketamine as an agent that "protects" the airway, but this is a relative rather than absolute protection: aspiration can still occur, and airway management equipment must always be immediately available. Ketamine is a potent bronchodilator, relaxing bronchial smooth muscle through sympathomimetic mechanisms and possibly through direct smooth muscle relaxation. This makes it the induction agent of choice for emergency airway management in patients with acute severe asthma, including status asthmaticus requiring intubation.⁵

CNS Effects and Intracranial Pressure. Ketamine increases cerebral blood flow, cerebral metabolic rate, and intracranial pressure. These effects are mediated through its sympathomimetic properties and through direct cerebral vasodilation. Historically, this led to a categorical contraindication to ketamine in patients with elevated intracranial pressure (ICP), including traumatic brain injury and intracranial mass lesions. This contraindication has been substantially revisited in the context of mechanically ventilated patients: when the airway is secured and ventilation is controlled (preventing the hypercapnia that amplifies ketamine's cerebral effects), the ICP increase with ketamine appears to be modest and clinically manageable, and several retrospective and prospective studies in ventilated TBI patients have found ketamine to be safe for sedation and procedures. In spontaneously breathing patients with known elevated ICP, the traditional contraindication remains reasonable clinical practice.⁵

Emergence Phenomena. Ketamine produces emergence phenomena in a proportion of patients, manifesting as vivid and often disturbing dreams, hallucinations, delirium, feelings of depersonalization or derealization, and frank psychosis in severe cases. The incidence in adults ranges from 5 to 30% in various studies and is substantially lower in children. Emergence phenomena are more common at higher doses, with rapid emergence, in adults (particularly women), and in patients with pre-existing psychiatric conditions or a history of psychedelic drug use. Benzodiazepine premedication (midazolam 1 to 2 mg IV) substantially reduces incidence and severity and should be administered prophylactically in adults receiving ketamine for procedures or induction of general anesthesia. A quiet recovery environment and minimizing auditory and tactile stimuli during emergence also reduce severity.¹

Subanesthetic and Analgesic Applications. At doses well below those required for dissociative anesthesia (0.1 to 0.5 mg/kg IV bolus, or 0.1 to 0.3 mg/kg/hr infusion), ketamine provides potent analgesia with minimal sedation. This subanesthetic dosing has become an important component of opioid-sparing multimodal analgesia protocols in perioperative and acute pain management. Mechanisms include NMDA receptor blockade (reducing central sensitization and opioid-induced hyperalgesia), opioid receptor agonism, and modulation of descending pain inhibitory pathways. Evidence supports perioperative subanesthetic ketamine infusions for reducing postoperative opioid consumption in major abdominal, thoracic, and orthopedic surgery.⁵ Ketamine is also used for procedural sedation and analgesia in the emergency department, particularly in children and in situations where maintaining spontaneous ventilation is advantageous.

Benzodiazepines are not primary anesthetic agents in the sense that they cannot reliably produce surgical anesthesia as sole agents at standard clinical doses, but they are among the most widely used adjuncts in anesthetic practice, contributing anxiolysis, anterograde amnesia, anticonvulsant activity, and minimum alveolar concentration (MAC)-sparing reduction of volatile agent requirements. Their mechanism is positive allosteric modulation of the gamma-aminobutyric acid type A (GABA-A) receptor at the benzodiazepine binding site, located at the interface of alpha and gamma subunits. Unlike barbiturates and propofol, benzodiazepines do not directly activate the GABA-A receptor in the absence of GABA; they enhance the affinity of GABA for its binding site and increase the frequency of chloride channel opening in response to GABA.⁷

Midazolam. Midazolam is the benzodiazepine of primary importance in perioperative anesthesia. It is water-soluble at the pH of its formulation (below 4) but undergoes ring closure to a lipid-soluble form at physiological pH following injection, enabling rapid CNS penetration. The onset of IV midazolam is 2 to 3 minutes, slower than propofol or thiopental, and the duration of sedation after a single dose is 45 to 90 minutes in most patients. Midazolam is hepatically metabolized by CYP3A4 (cytochrome P450 3A4) to 1-hydroxymidazolam, an active metabolite with approximately 10% of the potency of the parent compound, subsequently glucuronidated and renally excreted. In patients with renal failure, 1-hydroxymidazolam glucuronide accumulates and can prolong sedation significantly.⁷

Clinical uses of midazolam in anesthesia include: premedication (1 to 2 mg IV, producing anxiolysis and anterograde amnesia within 5 minutes); co-induction with propofol (midazolam 1 to 2 mg IV administered 2 to 3 minutes before propofol reduces the propofol induction dose by approximately 25 to 30%); prevention of ketamine emergence phenomena (1 to 2 mg IV before or with ketamine significantly reduces the incidence of hallucinations and dysphoria); and supplemental sedation during regional anesthesia. Midazolam is also used intraoperatively for amnesia as part of high-opioid cardiac anesthesia techniques where lighter hypnotic depths are used to preserve hemodynamics.¹

Diazepam and Lorazepam. Diazepam and lorazepam were historically important in anesthetic premedication and procedural sedation but have been largely displaced by midazolam in the perioperative setting because of their much longer durations of action and less predictable onset. Diazepam has an elimination half-life of 20 to 100 hours and an active metabolite (desmethyldiazepam) with a half-life of 36 to 200 hours; residual sedation persisting into the postoperative period is a significant clinical liability. Lorazepam's half-life is 10 to 20 hours, and its profound amnestic properties, while clinically useful in some ICU applications, make it unsuitable for ambulatory or short-duration anesthetic settings. Both retain roles in the treatment of intraoperative seizures, status epilepticus, and ICU sedation, but are not first-line perioperative premedicants where midazolam is available.⁷

Flumazenil. Flumazenil is a competitive benzodiazepine receptor antagonist that reverses benzodiazepine-induced sedation and respiratory depression. The onset of reversal after IV administration is approximately 1 to 2 minutes, with a duration of 30 to 60 minutes. Because the duration of flumazenil is considerably shorter than most benzodiazepines, resedation can occur after reversal, particularly with long-acting agents such as diazepam or lorazepam. Patients should therefore be monitored for at least 60 to 120 minutes after flumazenil administration before discharge from supervised care. Flumazenil can precipitate acute benzodiazepine withdrawal seizures in patients who are physically dependent on benzodiazepines, and it lowers seizure threshold in patients with epilepsy; it should be used with caution in these populations.⁷

Total intravenous anesthesia (TIVA) uses intravenous agents exclusively to provide hypnosis, analgesia, and (when required) neuromuscular blockade, without any contribution from inhalational agents. The standard TIVA technique combines propofol as the hypnotic agent with remifentanil as the analgesic; together these two agents cover the hypnotic and analgesic components of balanced anesthesia with individually titratable infusions. Neuromuscular blockade, when required, is provided by a nondepolarizing agent. The pharmacological rationale for this combination rests on the complementary pharmacokinetic profiles of propofol and remifentanil: propofol provides reliable hypnosis with a manageable context-sensitive half-time (CSHT) for prolonged infusions, while remifentanil provides potent, rapidly titratable analgesia with the shortest context-sensitive half-time of any opioid in clinical use (3 to 5 minutes regardless of infusion duration), enabling very fast offset at emergence.³

Remifentanil Pharmacology. Remifentanil is a mu-opioid receptor agonist that is unique among clinical opioids in its pharmacokinetic behavior. Its ester linkage renders it susceptible to hydrolysis by ubiquitous nonspecific esterases in plasma and tissues, producing a pharmacologically inactive carboxylic acid metabolite (GI90291). This metabolism is independent of hepatic and renal function and is so rapid that remifentanil has a true blood half-life of approximately 3 to 4 minutes and a context-sensitive half-time that remains approximately 3 to 5 minutes regardless of whether it has been infused for 30 minutes or 8 hours. This property makes remifentanil uniquely suitable for TIVA maintenance where precise and predictable offset is required. The standard TIVA maintenance infusion rate is 0.05 to 0.3 mcg/kg/min, titrated to surgical stimulation. Its potency is comparable to fentanyl on a weight basis. Opioid-induced hyperalgesia (OIH) is an important consideration with remifentanil: prolonged high-dose infusions may sensitize central pain pathways, increasing postoperative pain intensity above what would be expected from the surgical procedure alone. Perioperative ketamine or NSAIDs are often administered to mitigate OIH after remifentanil-based TIVA.³

Target-Controlled Infusion. Target-controlled infusion (TCI) systems use validated pharmacokinetic models to calculate and continuously adjust infusion rates in order to achieve a specified target plasma or effect-site drug concentration. The clinician enters a target concentration rather than an infusion rate, and the TCI pump continuously calculates the required infusion rate to approach and then maintain that target, using the three-compartment pharmacokinetic model parameters for the agent. For propofol, the Marsh and Schnider models are widely used, with the Schnider model incorporating patient age and lean body mass as covariates that adjust the pharmacokinetic parameters for individual patients. TCI is widely available on CE-marked infusion pumps in Europe, Canada, Australia, and many other countries; it is not FDA-approved in the United States, where weight-based manual infusion is standard.⁹

Effect-Site Targeting. The effect-site (Ce) targeting mode of TCI pumps targets drug concentration at the biophase (brain), rather than plasma, accounting for the equilibration lag between plasma concentration and drug effect. For propofol, the plasma-to-effect-site equilibration half-life (ke0) is approximately 2 to 3 minutes. Targeting effect-site concentration reduces the lag between infusion adjustment and clinical effect, allowing more responsive titration. In practice, effect-site TCI of propofol targets of 3 to 5 mcg/mL for maintenance during surgical stimulation and 1 to 2 mcg/mL for light sedation are typical, though substantial interindividual variability in pharmacokinetics and pharmacodynamics means that clinical endpoints (blood pressure, heart rate, movement) must always be used alongside TCI targets rather than relying on targets alone.⁹

Indications for TIVA over Inhalational Maintenance. TIVA is preferred over volatile agent maintenance in several well-defined clinical situations. In patients with known or suspected malignant hyperthermia susceptibility, all volatile halogenated agents are contraindicated and TIVA is obligatory. In patients at high risk for PONV (Apfel score 3 to 4), propofol-based TIVA reduces PONV incidence by approximately 25 to 30% relative to volatile agent maintenance, independent of antiemetic prophylaxis, and is recommended as a component of multimodal PONV prevention in high-risk patients. In cases requiring intraoperative motor evoked potential monitoring (spine surgery, cerebrovascular surgery, tumor resection near eloquent cortex), volatile agents suppress MEP amplitude prohibitively and TIVA with propofol-remifentanil is the required technique. For thoracic surgery involving one-lung ventilation, propofol does not inhibit hypoxic pulmonary vasoconstriction, preserving oxygenation during the period of lung isolation, whereas volatile agents attenuate HPV in proportion to their inspired concentration. In pediatric patients undergoing prolonged procedures where emergence agitation from sevoflurane is anticipated, propofol TIVA with remifentanil provides a smoother, more predictable emergence.¹³

Depth of Anesthesia Monitoring During TIVA. The principal challenge of TIVA relative to inhalational anesthesia is the absence of end-tidal gas concentration as a continuous surrogate for anesthetic depth. With volatile agents, the end-tidal concentration provides a continuous, reliable pharmacodynamic surrogate that correlates with depth of anesthesia. With TIVA, plasma propofol concentration can be estimated by the TCI pump model but cannot be directly measured at the bedside, and pharmacokinetic variability means that model predictions may diverge from true concentrations by 20 to 30% or more in individual patients. Processed electroencephalography (pEEG) monitoring provides an objective measure of brain activity that reflects anesthetic depth. The bispectral index (BIS), developed from a large database of EEG recordings during anesthesia, provides a dimensionless index from 0 (isoelectric) to 100 (fully awake), with the target range for surgical anesthesia typically 40 to 60. Other pEEG monitors (Patient State Index, Narcotrend, Entropy) use different signal processing algorithms but provide similar clinical information.⁹

The clinical evidence supporting pEEG monitoring to reduce awareness under anesthesia is strongest for TIVA. The B-Aware and B-Unaware trials examined BIS-guided versus standard anesthetic management; the B-Aware trial in high-risk patients showed a significant reduction in awareness with BIS monitoring, while B-Unaware in lower-risk patients showed no significant difference. Meta-analyses suggest that pEEG guidance reduces awareness incidence by approximately 50 to 80% in high-risk TIVA cases. TIVA-based anesthesia without any form of depth monitoring carries a higher awareness risk than volatile agent-based anesthesia (estimated at approximately 1 in 500 to 1 in 1,000 versus approximately 1 in 10,000 to 1 in 30,000 for volatile agents), and pEEG monitoring is considered standard of care for TIVA in many centers and guideline documents.⁹

Practical TIVA Management. A standard manual TIVA protocol for an adult patient uses a propofol induction dose of 1.5 to 2.0 mg/kg IV (reduced to 1.0 to 1.5 mg/kg if remifentanil is administered simultaneously), followed by propofol maintenance at 100 to 200 mcg/kg/min and remifentanil at 0.05 to 0.3 mcg/kg/min, both adjusted to clinical endpoints and pEEG target. Dedicated IV access for TIVA is advisable, as any interruption of propofol delivery (kinked line, disconnection, pump failure) can result in rapid awakening given propofol's short context-sensitive half-time. Prior to skin incision, remifentanil is increased to anticipate the nociceptive stimulus; after wound closure, remifentanil is reduced or stopped to facilitate rapid emergence. Propofol is typically stopped 5 to 10 minutes before the planned end of procedure. Because remifentanil provides no residual postoperative analgesia (its half-life is too short), transition to longer-acting analgesia (IV morphine, fentanyl, oral analgesics, regional techniques) must be planned and initiated before or immediately after stopping remifentanil to prevent an analgesic gap at emergence.³